BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma

Recent approvals of chimeric antigen receptor T-cells (CAR T) and bispecific antibody therapies offer new hope for relapsed refractory multiple myeloma (RRMM) patients, with superior efficacy over standard regimens observed in clinical trials. However, relapse after BCMA-directed therapy is common a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-10
Hauptverfasser:	Rashid, Aliya, Wesson, William, Abdallah, Al-Ola, Snyder, Jordan, Venkatesh, Priyanka, Mushtaq, Muhammad U., Shune, Leyla, Witek, Malgorzata A., McGuirk, Joseph P., Soper, Steven. A., Cui, Wei, Ahmed, Nausheen
Format:	Artikel
Sprache:	eng
Schlagworte:	BCMA CAR T Chimeric antigen receptor therapy Flow cytometry Minimal residual disease Myeloma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!